Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects

Disease Area:
Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)

Investigator: Donald Kohn

Institution: University of California, Los Angeles

CIRM Grant: CLIN2-09339-A (Closed)

Award Value: $10,156,925

Trial Sponsor: Orchard Therapeutics plc

Trial Stage: Phase 2

Trial Status: Completed

Targeted Enrollment: 10

ClinicalTrials.gov ID: NCT02999984

Details:
In ADA-SCID, allogeneic hematopoietic (blood) stem cell transplants from non-matched sibling donors are a high risk procedure. Additionally, the efficacy of chronic enzyme replacement therapy is uncertain in the long-term. A team at UCLA is using a patient’s own blood stem cells to try and rebuild the damaged immune systems of patients with ADA-SCID. They will use what’s called a lentiviral vector to deliver genetic material into the blood stem cells, correcting the genetic flaw that causes SCID. It’s hoped this will create a new blood system and a healthy immune system. Preliminary data indicates that OTL-101 - a stem cell gene therapy developed by UCLA and Orchard Therapeutics Limited - may significantly improve outcomes compared to available therapies.

Design:
Comparability of cryopreserved product versus fresh product.

Goal:

Updates:
Breakthrough Therapy Designation. Rare Pediatric Designation. Early evidence of safety and clinical efficacy in all treated patients.

News about this clinical trial:
Pioneering stem cell gene therapy cures infants with bubble baby disease
Study analyzes safety and effectiveness of stem cell gene therapy for bubble baby disease
Orchard Therapeutics announces that OTL-101 has received a Rare Paediatric Disease Designation